אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; mannitol; carnauba wax; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hydrogenated castor oil; stearic acid; macrogol 6000; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - coplavix is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). coplavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, coplavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate -

ישראל - אנגלית - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - tablets - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - ** secondary prevention of atherotrobmotic events:clopidogrel is indicated in:• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy** prevention of atherotrobmotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

ישראל - אנגלית - Ministry of Health

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - tablets - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin,clopidogrel hydrogen sulfate -

סינגפור - אנגלית - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch); (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) - tablet, film coated - 100 mg - (acetylsalicylic acid layer) acetylsalicylic acid (as acetylsalicylic acid granulated with starch) 100 mg; (clopidogrel layer) clopidogrel (as clopidogrel hydrogen sulfate form ii) 75 mg

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin,clopidogrel hydrogen sulfate -

אירלנד - אנגלית - HPRA (Health Products Regulatory Authority)

msn labs europe limited - clopidogrel hydrogen sulfate - film-coated tablet - clopidogrel

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - aspirin, quantity: 100 mg; clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; mannitol; carnauba wax; colloidal anhydrous silica; maize starch; microcrystalline cellulose; hydrogenated castor oil; stearic acid; macrogol 6000; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - apx-clopidogrel is a fixed-dose combination product intended as continuation of therapy in patients with acute coronary syndrome already initiated with separate clopidogrel and aspirin products: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). apx-clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, apx-clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; carnauba wax; microcrystalline cellulose; macrogol 6000; hyprolose; mannitol; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: iscover is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). iscover is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, iscover has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.